CLINICAL TRIALS PROFILE FOR OTREXUP PFS
✉ Email this page to a colleague
All Clinical Trials for OTREXUP PFS
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00335140 ↗ | Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma | Terminated | National Cancer Institute (NCI) | Phase 2 | 2006-12-01 | RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with primary central nervous system (CNS) lymphoma. |
| NCT00335140 ↗ | Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma | Terminated | Eastern Cooperative Oncology Group | Phase 2 | 2006-12-01 | RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with primary central nervous system (CNS) lymphoma. |
| NCT00439296 ↗ | ABT-751 With Chemotherapy for Relapsed Pediatric ALL | Terminated | Abbott | Phase 1/Phase 2 | 2006-05-22 | This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done to find the highest dose of ABT-751 that can be given safely in combination with other chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects. After a safe dose for ABT-751 given with chemotherapy has been found, the study will add additional patients to find out if ABT-751 (given at the maximal safe dose) when given with additional chemotherapy is an effective therapy for the treatment of children with relapsed ALL. It is expected that approximately 15-35 children and young adults will take part in this study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OTREXUP PFS
Condition Name
Clinical Trial Locations for OTREXUP PFS
Trials by Country
Clinical Trial Progress for OTREXUP PFS
Clinical Trial Phase
Clinical Trial Sponsors for OTREXUP PFS
Sponsor Name
